Data / Drug companies / Apnar Pharma LP
Apnar Pharma LP: 28 products in the FDA NDC directory, labeler code 24689
Apnar Pharma LP (labeler code 24689) lists 28 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 19 prescription drugs, 9 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 7, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 24689
- Products in commercial distribution
- 28
- Packages
- 40
- Finished drugs by generic name
- 14
- Prescription products
- 19
- Over the counter products
- 9
- Flagged as original packager
- 28 of 28 products that carry the flag
- Started marketing in the last 12 months
- 6
- Earliest marketing start
- October 1, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 16 | 57.1% |
| Over the counter monograph drugs | 9 | 32.1% |
| Other unapproved drugs | 3 | 10.7% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 19 | 67.9% |
| Over the counter drugs | 9 | 32.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Buspirone hydrochloride | 5 | 50 |
| Nebivolol hydrochloride | 4 | 5 |
| Terazosin hydrochloride | 4 | 15 |
| Meclizine hydrochloride | 3 | 41 |
| Hydrocortisone acetate | 2 | 35 |
| Eletriptan hydrobromide | 2 | 11 |
| Sodium bicarbonate | 1 | 51 |
| Hydroquinone | 1 | 12 |
| Pyridostigmine bromide | 1 | 20 |
| Diphenhydramine hcl | 1 | 99 |
| Docusate sodium | 1 | 79 |
| Lidocaine | 1 | 216 |
| Magnesium oxide | 1 | 13 |
| Guaifenesin | 1 | 123 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 15 | 53.6% |
| Capsule | 4 | 14.3% |
| Cream | 2 | 7.1% |
| Suppository | 2 | 7.1% |
| Capsule, liquid filled | 2 | 7.1% |
| Tablet, film coated | 2 | 7.1% |
| Solution | 1 | 3.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Terazosin hydrochloride | 24689-004 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Terazosin hydrochloride | 24689-003 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Terazosin hydrochloride | 24689-002 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Terazosin hydrochloride | 24689-001 | Capsule | Generic drugs (ANDA) | August 7, 2026 |
| Eletriptan Hydrobromide | 24689-168 | Tablet, film coated | Generic drugs (ANDA) | May 13, 2026 |
| Eletriptan Hydrobromide | 24689-167 | Tablet, film coated | Generic drugs (ANDA) | May 13, 2026 |
| Buspirone Hydrochloride | 24689-933 | Tablet | Generic drugs (ANDA) | June 17, 2024 |
| Buspirone Hydrochloride | 24689-921 | Tablet | Generic drugs (ANDA) | June 17, 2024 |
| Buspirone Hydrochloride | 24689-907 | Tablet | Generic drugs (ANDA) | June 17, 2024 |
| Buspirone Hydrochloride | 24689-785 | Tablet | Generic drugs (ANDA) | June 17, 2024 |
| Buspirone Hydrochloride | 24689-781 | Tablet | Generic drugs (ANDA) | June 17, 2024 |
| Pryidostigmine bromide | 24689-104 | Solution | Generic drugs (ANDA) | June 1, 2024 |
| Nebivolol | 24689-162 | Tablet | Generic drugs (ANDA) | May 13, 2024 |
| Nebivolol | 24689-161 | Tablet | Generic drugs (ANDA) | May 13, 2024 |
| Nebivolol | 24689-160 | Tablet | Generic drugs (ANDA) | May 13, 2024 |
| Nebivolol | 24689-159 | Tablet | Generic drugs (ANDA) | May 13, 2024 |
| Docusate sodium | 24689-130 | Capsule, liquid filled | Over the counter monograph drugs | September 25, 2023 |
| SleepAid (Diphenhydramine HCL) | 24689-154 | Capsule, liquid filled | Over the counter monograph drugs | May 4, 2023 |
| Meclizine Hydrochloride | 24689-146 | Tablet | Over the counter monograph drugs | November 21, 2022 |
| Guaifenesin | 24689-144 | Tablet | Over the counter monograph drugs | August 5, 2022 |
| Magnesium Oxide | 24689-132 | Tablet | Over the counter monograph drugs | August 5, 2022 |
| Meclizine Hydrochloride | 24689-139 | Tablet | Over the counter monograph drugs | July 29, 2022 |
| Meclizine Hydrochloride | 24689-138 | Tablet | Over the counter monograph drugs | July 29, 2022 |
| Sodium Bicarbonate | 24689-137 | Tablet | Over the counter monograph drugs | June 24, 2022 |
| Lidocaine 5% | 24689-124 | Cream | Over the counter monograph drugs | November 1, 2021 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.